Michael Petrosky, MD, of the Allegheny Health Network, discusses how monoclonal antibodies will help in the prevention of respiratory syncytial virus (RSV) in infants.
Michael Petrosky, MD, of the Allegheny Health Network, spoke about the potential impact of monoclonal antibodies on the prevention and treatment of respiratory syncytial virus (RSV) in infants.
Transcript
Do you see treatment for RSV becoming more proactive with the new monoclonal antibody?
I definitely agree with that, and living in the world of pediatrics, that's our big thing is prevention. That's why we're big on the vaccine schedules. That's why we have to see children every so often make sure they're growing and developing well, to just sort of help prevent serious issues or if we can catch things earlier, we know outcomes are definitely better. It'll definitely be more preventative. What's nice is we're able to get more kids vaccinated, get kids more immune to RSV, at least for the short amount of time, and with pretty much less of a hassle. If you only have to come in once to get the job done, as opposed to 5 times, it's definitely helpful. So it's going to get kids covered for longer periods of time and get more kids covered.
Will these monoclonal antibodies become as commonplace as the flu vaccine?
I think at this point, if this is what we have, then yes, it'll definitely help because we know this is really the only thing we have to cover to protect infants against RSV. Going back to your earlier question, where you mentioned other injections, immunizations come along. So there are actually vaccines for RSV, but it's for the older population, those 60 and older. And that's more that active immunization. I think, until we can get a good active vaccination program for infants, monoclonal antibodies will help. We know last year was pretty rough with RSV; it came a whole lot earlier than expected [and] lasted longer. So we know the more we can prevent [1 child] from getting it, that's 1 less child that can then pass it on to someone else. So we know, until we get something better, these monoclonal antibodies are going to be the best that we have to help prevent RSV in infants.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More